electroCore (NASDAQ:ECOR) Issues Earnings Results

electroCore (NASDAQ:ECOR) released its earnings results on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.14, FiscalAI reports. The business had revenue of $9.69 million for the quarter, compared to analyst estimates of $10.93 million.

Here are the key takeaways from electroCore’s conference call:

• electroCore reported record third-quarter net sales of $9.7 million, up 12% year over year, with gross margin expanding to 88.5%. Adjusted EBITDA loss narrowed to a company-low $700,000, although GAAP results included a $400,000 settlement gain and a $100,000 tax benefit.
• The company lowered its 2026 revenue outlook to $39 million–$42 million, saying sales-force changes delayed the acceleration it had expected in the second half. Management now anticipates 30%–40% revenue growth in 2027 and targets its first positive Adjusted EBITDA quarter by year-end 2027, both dependent on execution.
• Management cited early gains from its commercial overhaul: newer representatives generated about 30% more monthly VA revenue than the territories did before, and VA new-patient orders rose 21% year over year. Refill revenue reached a company high, while the national refill rate was 42% through September, below the company’s goal of more than 70%.
• electroCore filed an FDA 510(k) submission for Quell to treat chemotherapy-induced peripheral neuropathy (CIPN), a potential new market that management estimates at 600,000–700,000 U.S. patients. Clearance and any resulting sales remain uncertain; the company said CIPN-specific revenue is not included in its 2027 growth outlook.
• Cash, cash equivalents, and marketable securities fell to $7.5 million from $10 million at the end of the prior quarter. The company is evaluating a term-loan refinancing to support its runway, but said it has no agreement in place.

electroCore Stock Performance

Shares of ECOR traded down $0.86 during mid-day trading on Friday, reaching $7.93. 46,300 shares of the company’s stock traded hands, compared to its average volume of 88,124. The business’s 50-day moving average price is $9.33 and its 200-day moving average price is $7.76. The stock has a market capitalization of $71.57 million, a P/E ratio of -5.71 and a beta of 1.23. electroCore has a 12 month low of $4.41 and a 12 month high of $12.70.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of electroCore in a report on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $18.00.

Insider Transactions at electroCore

In other electroCore news, CFO Joshua S. Lev sold 3,000 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $9.36, for a total value of $28,080.00. Following the sale, the chief financial officer directly owned 84,889 shares in the company, valued at approximately $794,561.04. The trade was a 3.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Thomas Errico bought 5,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was acquired at an average price of $9.82 per share, for a total transaction of $49,100.00. Following the completion of the acquisition, the director directly owned 363,904 shares in the company, valued at approximately $3,573,537.28. This represents a 1.39% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have sold 20,000 shares of company stock worth $200,120. Company insiders own 7.80% of the company’s stock.

About electroCore

electroCore, Inc (NASDAQ: ECOR) is a commercial-stage medical device company focused on bioelectronic medicine and non-invasive vagus nerve stimulation (nVNS). Its technology is designed to stimulate the vagus nerve through the neck without requiring surgery or implanted components.

The company’s primary prescription product is gammaCore, a handheld nVNS device used for the acute treatment of pain associated with migraine and episodic cluster headaches in adults. electroCore also markets consumer-oriented products, including Truvaga, a handheld vagus nerve stimulation device positioned for general wellness applications.